EURACTIV logo

Commission calls for changes in drugs patent rules for developing countries

07-03-2002 (updated: 29-01-2010 )

Languages: Français | Deutsch

The EU has presented a proposal to the WTO concerning access to medicines for developing countries that do not have the capacity to produce them themselves.

On 5 March 2002, the WTO Council on Trade-Related Aspects of Intellectual Property Rights (TRIPS) met in Geneva. The EU presented its proposal as to how the patent agreement should be modified to support countries that cannot themselves produce the drugs. The EU suggests amendments to Articles 30 and 31f of the TRIPS agreement, to allow for medicines to be produced elsewhere and exported under “compulsory licensing” to the country in need. The export would need to be strictly controlled to ensure that the drugs do not reach other markets.

 

Background

At the WTO negotiations in Doha in November 2001, an agreement was reached to ease patent rules to allow developing countries to produce patented drugs under a procedure called "compulsory licensing". This way countries struck by health crise such as HIV, are given access to affordable medicines. (see also EURACTIV13 November 2001)

 

Timeline

The TRIPS Council must report to the WTO General Council before the end of 2002.

 

EURACTIV's editorial content is independent from the views of our sponsors.

Languages: Français | Deutsch

Do you value EURACTIV’s reporting? We need your support.

Dear reader,

Media is a pillar of democracy – as long as it can function properly. Now more than ever we need unbiased, expert information on how and why the European Union functions. This information should not be behind a paywall, and we remain committed to providing our content for free.

We know our readers value our reporting. We know journalism that covers the EU in a clear, unbiased way is critical to the future of the European Union.

And we know your support is critical for ensuring this independent and free journalism.

Don’t take the media sector for granted. It was already fragile before the coronavirus pandemic. And as people can’t meet, media companies have lost a major source of revenue: events. EURACTIV is supported by a mix of revenue streams including sponsorships, online advertising, EU-funded projects, and policy debates. All of these sources of revenue are impacted by the current crisis. 

 

While media struggles, disinformation thrives. We are already seeing fearmongering, fake news about the EU response, and increased threats to freedom of the press.


For more than two decades we have provided free, independent, multilingual reporting on the European Union. We continue to believe in Europe, and we hope you do too. 

Your financial support at this critical time will allow our network of newsrooms across Europe to continue their work when Europe needs it most.

Support EURACTIV Media Network for Europe and CONTRIBUTE today. 

Topics  

Subscribe to our newsletters

Subscribe
Contribute